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reflect the clinical importance of the recommendations. 
Recommended best practice (“good practice points”), 
based on the clinical experience of the guideline devel-
opment group, is also indicated (as GPP). 
Diagnosis and assessment in primary care
•  Diagnose chronic plaque psoriasis (psoriasis 
vulgaris) on the basis of well demarcated bright 
red plaques covered by adherent silvery white 
scales affecting any body site, often symmetrically, 
especially the scalp and extensor surfaces of limbs. 
The differential diagnosis includes eczema, tinea, 
lichen planus, and lupus erythematosus (GPP).
•  Generalised pustular psoriasis (fig 2) is rare and 
is characterised by the development of numerous 
sterile non-follicular pustules within plaques of 
psoriasis or on red tender skin. This may occur 
acutely and be associated with fever. The differential 
diagnosis includes pyogenic infection, vasculitis, 
and drug eruptions (GPP).
GUIDELINES
Diagnosis and management of psoriasis and psoriatic 
arthritis in adults: summary of SIGN guidance
A D Burden,1 M Hilton Boon,2 J Leman,3 H Wilson,4 R Richmond,5 A D Ormerod,6 7 on behalf of the Guideline 
Development Group 
1Alan Lyell Centre for Dermatology, 
Western Infirmary, Glasgow, UK
2Scottish Intercollegiate Guidelines 
Network (SIGN), Glasgow
3Western Infirmary, Glasgow
4Stobhill Hospital, Glasgow
5Borders General Hospital, 
Melrose, UK
6Department of Applied Medicine, 
University of Aberdeen, Aberdeen, UK
7Aberdeen Royal Infirmary, Aberdeen
Correspondence to: M Hilton Boon  
michele.hiltonboon@nhs.net  
Cite this as: BMJ 2010;341:c5623
doi: 10.1136/bmj.c5623 
The degree of disability and negative impact on qual-
ity of life caused by psoriasis and psoriatic arthritis are 
comparable to those of ischaemic heart disease, dia-
betes, depression, and cancer.1 Severe psoriasis and 
psoriatic arthritis are associated with an increased risk 
of conditions such as cardiovascular disease, diabetes, 
and depression.2-5 P soriatic arthritis is underdiagnosed; 
about a fifth of patients with psoriasis also have psori-
atic arthritis.6 The management of patients with both 
conditions may be particularly challenging and require 
close collaboration among several specialties. This arti-
cle summarises the most recent recommendations from 
the Scottish Intercollegiate Guidelines Network (SIGN) on 
the diagnosis and management of psoriasis and psoriatic 
arthritis in adults.7
Recommendations
SIGN recommendations are based on systematic reviews 
of best available evidence. The strength of the evidence 
is graded as A, B, C, or D (fig 1), but the grading does not 
Fig 2 | Generalised pustular psoriasisFig 1 | Explanation of SIGN grades of recommendations 
The grade of recommendation relates to the strength of the supporting evidence on which 
the evidence is based. It does not reflect the clinical importance of the recommendation
• At least one high quality meta-analysis, systematic review of randomised controlled trials, or 
randomised controlled trial with a very low risk of bias and directly applicable to the target 
population; or
• A body of evidence consisting principally of well conducted meta-analyses, systematic 
reviews of randomised controlled trials, or randomised controlled trials with a low risk of bias 
directly applicable to the target population, and demonstrating overall consistency of results
A
• A body of evidence including studies rated as high quality systematic reviews of case-control 
or cohort studies, and high quality case-control or cohort studies with a very low risk of 
confounding or bias and a high probability that the relation is causal and that are directly 
applicable to the target population, and with overall consistency of results; or
• Extrapolated evidence from studies described in A
B
• A body of evidence including well conducted case-control or cohort studies with a low risk of 
confounding or bias and a moderate probability that the relation is causal and that are directly 
applicable to the target population and with overall consistency of results; or
• Extrapolated evidence from studies described in B
C
• Non-analytic studies, such as case reports, case series, expert opinion;  or
• Extrapolated evidence from studies described in C
D
Good Practice Points (GPP)
Recommended best practice based on the clinical experience of the guideline development 
group
This is one of a series of BMJ 
summaries of new guidelines 
based on the best available 
evidence; they highlight 
important recommendations for 
clinical practice, especially where 
uncertainty or controversy exists.
Further information about the 
guidance, a list of members of the 
Guideline Development Group, 
and an algorithm are in the full 
version on bmj.com.
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or generalised pustular psoriasis to a dermatology 
department as an emergency (D).
•  Refer all patients suspected as having psoriatic 
arthritis to a rheumatologist for an early diagnosis 
and appropriate escalation from treatment with 
disease modifying antirheumatic drugs to treatment 
with anti-tumour necrosis factor, if required, thereby 
reducing joint damage (B).
•  For guttate psoriasis, consider early referral for 
consideration of phototherapy in those who fail to 
respond to topical treatment (GPP).
Treatment
•  Encourage a healthy lifestyle with regular exercise, 
weight management, cessation of smoking, and 
moderation of alcohol consumption (D).
• Encourage patients to be actively involved in their 
care management (D). Discuss treatment options, 
risks, and benefits with the patient, allowing them 
more opportunity to be involved in decision making 
(D).
• To improve concordance, keep the number of 
treatments a day to a minimum (D).
Topical treatments
•  Consider regular application of emollient to reduce 
scaling and to help with other symptoms, including 
itch (GPP).
•  In plaque psoriasis, offer short term, intermittent, 
potent topical corticosteroids or a combined potent 
corticosteroid plus calcipotriol ointment for rapid 
improvement (A). Avoid regular use of potent to 
very potent topical corticosteroids for prolonged 
periods because of the risk of long term adverse 
effects, such as cutaneous atrophy (D). For long term 
use, a vitamin D analogue is appropriate. Choose 
calcipotriol first, but if this causes troublesome 
local irritation, switch to an alternative vitamin D 
analogue (A). If a vitamin D analogue is ineffective 
or not tolerated then consider coal tar (solution, 
cream, or lotion), tazarotene gel, or short contact 
dithranol (30 minute exposure in patients with a few 
relatively large plaques of psoriasis) (B).
•  In scalp psoriasis, offer short term intermittent use 
of potent topical corticosteroids or a combination of 
a potent corticosteroid and a vitamin D analogue (B).
•  For patients with thick scaling of the scalp, treat 
initially with overnight application of salicylic acid, 
•  Diagnose guttate psoriasis (fig 4) on the basis of 
the development over a period of one to seven 
days of multiple small papules of psoriasis over 
wide areas of the body. The differential diagnosis 
includes pityriasis rosea, viral exanthems, and drug 
eruptions (GPP).
•  Consider patient administered screening 
questionnaires such as the psoriasis epidemiology 
screening tool (PEST) for early detection of psoriatic 
arthritis in patients with articular symptoms (C).8
•  Suspect psoriatic arthritis in patients with psoriasis 
who develop early morning stiffness lasting more 
than 30 minutes, spinal stiffness that improves 
with exercise, joint swelling, joint tenderness, or 
dactylitis (diffusely swollen or “sausage” digit) 
(GPP).
•  Review patients annually (GPP). As part of the 
review:
- Optimise topical treatment (see later 
recommendations) (GPP)
- Document disease severity using the dermatology 
life quality index (see box outlining online 
assessment tools) (D)
- Assess for symptoms of arthritis (D)
- Screen for depression (D)
- In patients with severe disease, measure body mass 
index, blood pressure, and lipid profile, and screen 
for diabetes mellitus (D).
Referral
•  Offer dermatology referral for patients who fail to 
respond to topical treatment and who score >5 on 
the dermatology life quality index (D).
•  Refer patients with erythrodermic psoriasis (fig 3) 
Fig 3 | Erythrodermic psoriasis
Fig 4 | Guttate psoriasis
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tar preparations, or oil preparations (such as olive 
oil, coconut oil) to remove thick scale (GPP).
•  In nail psoriasis, consider topical corticosteroids, 
salicylic acid, calcipotriol, or tazarotene used alone 
or in combination (GPP).
•  In facial and flexural psoriasis, offer moderate 
potency topical corticosteroids for first line short 
term use (B). In patients who fail to respond to this, 
offer vitamin D analogues or tacrolimus ointment 
for intermittent use if tolerated (B). Avoid using 
treatments with irritant properties (dithranol, 
topical retinoids) in flexural sites (GPP).
Secondary care—psoriatic arthritis
•  Dermatology and rheumatology teams should work 
closely together to manage patients with severe 
joint and skin disease (GPP). Aim for monotherapy 
that treats both skin and joint disease rather than 
multiple therapies (GPP).
•  Offer methotrexate to treat psoriatic arthritis (C), 
especially when associated with severe  cutaneous 
psoriasis (GPP).
•  For patients with peripheral psoriatic arthritis, 
offer the disease modifying antirheumatic drug 
leflunomide (A), or sulfasalazine as an alternative 
(C).
•  Offer treatment with a biologic drug (adalimumab, 
etanercept, or infliximab) to patients with active 
psoriatic arthritis who have failed to respond to, are 
intolerant of, or have had contraindications to at 
least two disease modifying drugs (A).
•  Insufficient evidence exists to support a 
recommendation on the use of ciclosporin in 
psoriatic arthritis. Patients should not be expected 
to have failed to respond to ciclosporin before being 
eligible for treatment with a biologic drug (GPP).
Secondary care—psoriasis
•  For patients with psoriasis who do not respond to 
topical treatment, offer narrow band ultraviolet 
B phototherapy (B). For patients who fail this 
phototherapy, consider psoralen plus ultraviolet A 
photochemotherapy (B). Advise patients against the 
use of a sunbed as a source of ultraviolet light for 
treatment (GPP).
•  For patients with severe or refractory psoriasis, 
consider systemic treatment with ciclosporin, 
methotrexate, or acitretin after discussion of 
benefits and risks (B):
- Offer methotrexate for longer term use and where 
there is concomitant psoriatic arthritis (B)
- Offer ciclosporin for short term intermittent use (A)
- Consider acitretin as an alternative (B) except in 
women of childbearing potential (GPP).
•  For patients who are not suitable for the above 
systemic treatments, consider fumaric acid esters 
as an alternative maintenance treatment (B).
•  Offer biologic drugs (adalimumab, etanercept, 
infliximab or ustekinumab) to patients with 
severe psoriasis who fail to respond to, who 
have a contraindication to, or are intolerant of 
phototherapy and other systemic treatments 
including ciclosporin and methotrexate (A).
•  Offer those who have started or switched systemic 
treatments or biologic drugs the opportunity to 
enrol on the British Association of Dermatologists 
Biologics Intervention Register (BADBIR) for 
assessment of long term relative safety (GPP).
•  Ensure that inpatient treatment on a dermatology 
ward is available for patients with severe psoriasis 
(D).
•  Consider nurse led clinics to deliver services such 
as follow-up of specialist caseload, repeat access 
for patients with recurrent disease, and monitoring 
of systemic treatments (D).
Overcoming barriers
Resources are needed in primary care for an annual 
review of patients that fully evaluates the impact of 
these diseases on quality of life, identifies those patients 
with more severe disease who require specialist services, 
and assesses comorbid conditions such as depression 
and vascular disease. In secondary care, clinical time 
needs to be made available for multidisciplinary care 
that optimises patient outcomes over the longer term, 
in the face of pressures to prioritise new patients. The 
increased resources required for phototherapy, systemic 
treatments, biologic treatments, and inpatient treat-
ments are substantial. 
Undergraduate and postgraduate medical education 
needs to reflect the prevalence and importance of pso-
riasis and psoriatic arthritis in the population. General 
practitioners may not have received specific rheumatol-
ogy or dermatology training and consequently may need 
training in diagnosing, assessing, and managing these 
conditions. Specialists need to embrace the new con-
cepts around understanding and treating comorbidities 
of psoriasis and psoriatic arthritis and remain conver-
sant with a rapidly developing therapeutic area.
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Online assessment tools for psoriasis and psoriatic 
arthritis
•	Dermatology	life	quality	index	(DLQI)—www.dermatology.
org.uk/quality/quality-dlqi.html
•	Psoriasis	area	severity	index	(PASI)	calculator—http://
pasi.corti.li/
•	Psoriasis	epidemiology	screening	tool	(PEST)	
questionnaire—www.arthritisresearchuk.org/arthritis_
information/information_for_medical_profes/hands_
on/summer_2009.aspx#non
•	Bath	ankylosing	spondylitis	disease	activity	index	
(BASDAI)—http://basdai.com/BASDAI.php
•	Bath	ankylosing	spondylitis	functional	index	(BASFI)—
http://basdai.com/BASFI.php
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Managing Parkinson’s disease during surgery
K A Brennan,1 R W Genever2
Parkinson’s disease is a common condition affecting over 
100 000 people in the UK.1 People with Parkinson’s dis-
ease who undergo surgery have increased mortality and 
longer hospital stays than people without this condition.2 
Missing dopaminergic medication during a period of peri-
operative starvation can result in life threatening compli-
cations.3 4 This problem can be further compounded if 
the absorption of drugs is impaired.5 Recognising these 
hazards is the first step in an approach that may reduce 
the risk of suboptimal medication faced by people with 
Parkinson’s disease, using three principles.
• Advance planning
• Appropriate prescribing
• Advice from specialists.
Methods
We reviewed the available literature using PubMed and 
Google scholar databases up to May 2010. Further papers 
were identified from the references of articles found by 
the initial search. We also searched the Cochrane Library. 
Much of the evidence was based on case reports so selec-
tion of papers according to the grade of evidence was not 
attempted. A study published in July 2010 that added 
substantial new evidence was included.
People with Parkinson’s disease undergoing 
surgery are at increased risk owing to their 
condition and to potential omission of 
medication. This article looks at what doctors 
need to consider in this situation and how 
specialist assistance can be accessed
Potential complications of missing medication
The consequences of missing Parkinson’s medica-
tion can vary enormously. Some people can tolerate a 
missed tablet without experiencing any major effects. 
Others become immobile. However, in some situations, 
missing dopaminergic medication can precipitate a con-
dition known as neuroleptic malignant like syndrome, 
associated with fever, confusion, raised concentrations 
of muscle enzyme, and even death. This syndrome is 
most common in people with more severe Parkinson’s 
symptoms and those on the largest doses of levodopa.6
What particular risks are faced?
Some of the risks relate to Parkinson’s disease itself and 
others to the effects of omitting medication. A retrospec-
tive cohort study of 234 people with Parkinson’s disease 
and 40 979 controls undergoing major abdominal surgery 
found a higher incidence of aspiration pneumonia, bacte-
rial infection, and urinary tract infection in the group with 
Parkinson’s.2
Case reports have described other perioperative com-
plications in people with Parkinson’s disease, includ-
ing postoperative respiratory failure and postextubation 
laryngospasm. Other reports mention exacerbation of 
Parkinson’s symptoms during surgery and a case of severe 
neuroleptic malignant like syndrome precipitated by peri-
operative starvation for coronary artery bypass grafting.3  4
Access to the correct medication at the right time remains 
a problem for people with Parkinson’s disease when they 
are admitted to hospital. This concern has led to a national 
awareness campaign from the charity Parkinson’s UK.7 Lack 
of awareness of the importance of maintaining medication 
at the time of surgery places patients at increased risk.
1 Rapp SR, Feldman SR, Exum ML, Fleischer ABJr., Reboussin DM. Psoriasis 
causes as much disability as other major medical diseases. J Am Acad 
Dermatol 1999;41(3 Pt 1):401-7.
2 Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of 
myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41.
3 Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction 
and other vascular diseases in patients with psoriasis. Br J Dermatol 
2008;159:895-902.
4 Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. 
Prevalence of cardiovascular risk factors in patients with psoriasis. J Am 
Acad Dermatol 2006;55:829-35.
5 Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial 
burden of psoriasis. Am J Clin Dermatol 2005;6:383-92.
6 Reich K, Kruger K, Mossner R, Augustin M. Epidemiology and clinical 
pattern of psoriatic arthritis in Germany: a prospective interdisciplinary 
epidemiological study of 1511 patients with plaque-type psoriasis. Br J 
Dermatol 2009;160:1040-7.
7 Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis  
and management of psoriasis and psoriatic arthritis (SIGN guideline 121). 
2010. www.sign.ac.uk/guidelines/fulltext/121/index.html.
8 Ibrahim G, Buch M, Lawson C, Waxman R, Helliwell PS. Evaluation of an 
existing screening tool for psoriatic arthritis in people with psoriasis and 
development of a new instrument: the psoriasis epidemiology screening 
tool (PEST) questionnaire. Clin Exp Rheumatol 2009;27:469-74.
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Reducing the risks
Advance planning
As part of a Parkinson’s disease education programme, 
patients should be encouraged to ask that their move-
ment disorder team is consulted before admission. This 
will enable those at greatest risk to be identified and their 
treatment individually tailored. The referral could come 
from the patient’s general practitioner, the surgical out-
patient department, or the pre-assessment clinic.
The aim is to establish whether the patient’s treatment 
regimen should be altered for the period around their 
operation and to consider any additional measures that 
might be preferable.
Who should give the specialist advice?
Where available, a nurse specialising in Parkinson’s 
disease can play a key part. They may be able to advise 
directly or discuss the case with the patient’s consult-
ant. In areas without specialist nurse support the advice 
should come directly from the patient’s geriatrician or 
neurologist.
Unplanned surgery and complicated elective surgery
Specialist preoperative advice cannot always be 
obtained, particularly for urgent surgery. To allow a treat-
ment plan to be enacted at any time, we recommend that 
hospitals develop a protocol for this situation. We pro-
pose a flowchart (figure) to guide a non-specialist until 
more specific advice can be obtained from the movement 
disorder team.8  9 Clinicians who are unfamiliar with med-
ication for Parkinson’s disease may require assistance 
from a pharmacist.
Anaesthetic and surgical considerations
Pre-operative
All patients having surgery under general or regional 
anaesthetic require preoperative fasting. However, it 
is recognised that it is safe to continue clear oral fluids 
up to 2 h before elective surgery.10 It is routine practice 
to continue oral medications until the time of anaes-
thetic induction. This practice should be encouraged in 
patients with Parkinson’s. Consideration should be given 
to placing such patients at the start of the operating list, 
facilitating greater predictability over the time of fasting 
and surgery, and ensuring optimum early postoperative 
disease management.
Induction—regional versus general anaesthesia
Several factors affect the choice of anaesthesia. Regional 
anaesthesia allows monitoring of Parkinson’s symp-
Patient requires review from movement disorder specialist at earliest opportunity
Adjusted LEDD >350 mgAdjusted LEDD ≤350 mg
Prescribe apomorphine
Calculate estimated equivalent dose of subcutaneous apomorphine
= Adjusted LEDD/240 mg per hour
= ___ mg per hour
Remember to pre-load with domperidone
Prescribe rotigotine
Calculate estimated equivalent dose of rotigotine
= Adjusted LEDD/20 mg
= ___ mg
Round to nearest 2 mg (up to 16 mg) and prescribe once daily
Patient requiring parenteral treatment Indications for parenteral medication
  (both conditions need to be satisfied)
• Delay to oral treatment predicted
• Ileus or other cause of poor drug
     absorption likely
*Estimate levodopa equivalent dose by
  multiplying by LEF
Drug
Pergolide
Lisuride
Pramipexole (base)
Cabergoline
Ropinirole
Rotigotine
Bromocryptine
Apomorphine
LEF
100
100
100
100
20
20
10
10
Is patient on levodopa?
mg
X 0.7
Controlled release L-dopa?
COMT inhibitor?
Calculate total daily levodopa dose
(not including carbidopa/benserazide)
Adjusted total levodopa dose = ___ mg
(Total A) A=0 if not on levodopa
Yes
Yes
NoNo
mg
Is patient on a dopamine agonist?
Total A + total B =  ___ mg (LEDD)Adjust LEDD to reduce side effects
X 0.55 Adjusted LEDD = ___ mg
Calculate total dopamine agonist dose
Equivalent  total levodopa dose = ___ mg
(Total B) B=0 if not on dopamine agonist
Yes No
mg
X LEF
What is LD equivalent
factor (LEF)? *1
Yes
No
X 1.3
Algorithm for estimating parenteral doses of drugs for Parkinson’s disease
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toms and should be considered in people who require 
very frequent dopaminergic medication. In exceptional 
c ircumstances oral medication can be administered intra-
operatively, although a case of exacerbation of parkinson-
ism despite using this approach has been reported.3
Some motor symptoms of Parkinson’s disease, such as 
severe dyskinesia, might make a general anaesthetic pref-
erable. The anaesthetist should be aware of the effects of 
routinely used anaesthetic drugs on parkinsonism. Propo-
fol is commonly used to induce anaesthesia and two case 
studies have shown that it can exacerbate dyskinesia.11 
However, propofol may temporarily suppress tremor asso-
ciated with Parkinson’s disease12so it continues to be the 
first choice of most anaesthetists. Its antiemetic effect may 
also be beneficial.
The need for intubation should be assessed on an indi-
vidual basis. Severe Parkinson’s disease is associated with 
excessive salivation that is often due to swallowing dys-
function. If dysphagia is suspected, intubation is the safer 
choice. In these patients, anticholinergics can increase 
the viscosity of saliva, further impairing swallowing, and 
should be used with caution.13
Intraoperative
Antiemetics are routinely given intraoperatively. Cen-
trally acting dopamine antagonists such as prochlo-
rperazine and metoclopramide are likely to exacerbate 
Parkinson’s disease. Domperidone is preferable as it has 
a largely peripheral mode of action and may be given as 
a s uppository. Other appropriate anti-emetics include 
5-hydro xytryptamine-3 antagonists such as ondansetron 
and the antihistamine cyclizine.
Some patients will have a deep brain stimulator in situ 
and this should be recorded prominently in the medical 
notes. Electrocautery may damage the intracranial leads 
hence the manufacturers recommend its avoidance. 
However, where necessary, bipolar diathermy should be 
used.14
Post-operative
An assessment of Parkinson’s disease should be made 
at the earliest opportunity and a judgement made about 
the patient’s ability to absorb enteral medication. A strict 
nil-by-mouth instruction or active vomiting will mandate 
an alternative route. The need for parenteral medication 
is extended in the presence of ileus or delayed gastric 
emptying. Advice from the Parkinson’s disease special-
ist nurse or consultant should be sought.
Appropriate prescribing
The overall strategy should be to maintain Parkinson’s 
treatment that closely resembles the patient’s usual 
t reatment. Several changes can be recommended, 
depending on the particular drugs in use and the nature 
of surgery.
Using a different preparation of the same drug treatment
Patients who usually receive levodopa can be given 
dispersible co-beneldopa via a nasogastric tube during 
lengthy surgery. A patient with severe Parkinson’s disease 
undergoing liver resection was maintained without appar-
ent exacerbation of his condition using this approach. 
Previous operations had resulted in marked rigidity and 
inability to swallow secretions in the same patient.15
This technique is unsuitable when evidence indicates 
paralytic ileus. Two cases of worsening parkinsonism 
have been reported in patients whose recovery was com-
plicated by ileus despite receiving orally disintegrating 
co-careldopa.5
When switching from controlled release levodopa to 
dispersible co-beneldopa a dose reduction of around 
30% is suggested due to lower bioavailability in control-
led release form.16  17
Using alternative Parkinson’s drugs in the  
perioperative period
Enteral medication would not be appropriate for a patient 
in whom post-operative ileus or delayed gastric emptying 
is expected. The choices for this patient are suboptimal 
treatment with its associated risks, or a parenteral drug 
(apomorphine or rotigotine).
Apomorphine is a highly potent dopamine agonist 
which is delivered subcutaneously. Switching a patient 
from oral treatment to apomorphine for the duration of 
surgery would avoid the problems of drug absorption 
seen with paralytic ileus. Due to its high potency, even 
patients on large doses of treatment are likely to get effec-
tive control of their symptoms from apomorphine. The 
main disadvantages are emetogenesis (which necessitates 
concomitant use of domperidone), neuropsychiatric side-
effects such as hallucinations, and hypotension.
Rotigotine is a relatively new agent. It is also a 
dopamine agonist and is delivered transdermally with a 
patch. In an open label study, 14 patients were switched 
from their usual treatment to rotigotine the day before 
they underwent surgery. The switchover was felt by clini-
cians and patients to be easy and only one patient had 
a side effect (transient hallucinations and nausea) that 
was likely to have been caused by their medication.18 Its 
advantages are ease of use and tolerability but it may not 
be sufficiently potent to provide adequate treatment for 
patients on higher dose treatment regimens.
Switching to apomorphine or rotigotine
A number of articles have proposed levodopa equivalent 
doses for the various treatments. By using these data and 
head-to-head studies of rotigotine and ropinirole, it is 
possible to construct an estimated dose equivalent table 
for all the currently available drugs (see figure).8  9 In this 
situation our practice is to initially prescribe a lower than 
equivalent dose to reduce the risk of side effects but early 
review and adjustment of the dose is recommended.
Advice from a specialist
Even with an agreed advance plan or a written protocol, 
patients who do not rapidly regain the ability to take 
their usual Parkinson’s medication should be seen by a 
P arkinson’s disease specialist nurse or movement disorder 
consultant at the earliest opportunity. This allows the treat-
ment plan to be adjusted according to the initial response.
Review of Parkinson’s patients by a neurologist follow-
ing knee replacement has been shown to reduce length of 
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stay. 19 Further research is required to establish whether 
this benefi t can be transferred to Parkinson’s patients 
undergoing diff erent types of surgery. 
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 PICTURE QUIZ 
 A 35 year old smoker with shortness of breath 
	1		 Multiple	cysts,	ground	glass	opacities,	and	fibrotic	changes	are	the	main	abnormalities	
seen	on	these	images.	
	2		 The	differential	diagnoses	include	smoking	related	interstitial	lung	diseases	
(desquamative	interstitial	pneumonia,	respiratory	bronchiolitis-interstitial	lung	disease,	
pulmonary	Langherhans’	cell	histiocytosis),	sporadic	lymphangioleiomyomatosis,	
idiopathic	interstitial	pneumonias	(atypical	form	of	idiopathic	pulmonary	fibrosis,	fibrotic	
form	of	non-specific	interstitial	pneumonia),	and	chronic	hypersensitivity	pneumonia.	
	3		 Bronchoalveolar	lavage	and	a	differential	cell	count	on	the	fluid	obtained	(to	look	for	
lymphocytosis,	pigmented	macrophages,	and	CD-1a	cells).	A	surgical	lung	biopsy	
should	be	performed	when	the	images	on	high	resolution	computed	tomography	are	not	
typical	of	a	specific	interstitial	lung	disease,	as	in	this	case.	The	biopsy	showed	areas	of	
subpleural	fibrosis	as	well	as	bronchocentric	fibrosis	with	occasional	fibroblastic	foci.	
	4		 The	consensus	after	the	multidisciplinary	approach	was	that	the	diagnosis	was	chronic	
hypersensitivity	pneumonia	as	a	result	of	misuse	of	cocaine.	
	5		 Drug	discontinuation	is	essential.	Although	the	use	of	steroids	is	controversial,	
methylprednisolone	and	cyclophosphamide	were	used	to	treat	pulmonary	fibrosis.	
 STATISTICAL QUESTION 
 The Normal distribution 
	Answers		a	,		b	,		c	,	and		d	are	all	true.	
 ON EXAMINATION QUIZ 
 A patient with splenomegaly 
	Answer	D	is	correct.	
Fig 1 | High resolution computed tomography of the 
chest showing multiple cysts in the upper lung zones 
Fig 2 | High resolution computed tomography of the 
chest showing ground glass opacities and fibrotic 
changes in the lower lung zones
